Vort John Vander insider trades: Aratana Therapeutics (PETX) stock buys and sales
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Vort reports to the SEC
and 3 more companies
Open-market buys and sales
17 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Mar 6, 2015 | PETX | ↓ Sell | 6,137 | $20.01 | $123K | Direct | Mar 6, 2015 (0d) |
| Jul 30, 2013 | CNAT | ↑ Buy | 165,265 | $11.00 | $1.8M | Indirect | Aug 1, 2013 (2d) |
| Jul 2, 2013 | PETX | ↑ Buy | 500,000 | $6.00 | $3.0M | Indirect | Jul 2, 2013 (0d) |
| Mar 11, 2013 | PCRX | ↓ Sell | 500,000 | $27.86 | $13.9M | Indirect | Mar 13, 2013 (2d) |
| Feb 8, 2012 | PCRX | ↑ Buy | 535,714 | $7.00 | $3.7M | Indirect | Feb 10, 2011 (0d) |
| Feb 1, 2012 | VSTM | ↑ Buy | 100,000 | $10.00 | $1.0M | By Funds | Feb 3, 2012 (2d) |
| Nov 21, 2011 | PCRX | ↑ Buy | 461,538 | $6.50 | $3.0M | Indirect | Nov 22, 2011 (1d) |
| Feb 12, 2009 | PLIN | ↑ Buy | 2,248 | $8.11 | $18K | Indirect | Feb 12, 2009 (0d) |
| Feb 9, 2009 | PLIN | ↑ Buy | 999 | $8.00 | $8K | Indirect | Feb 10, 2009 (1d) |
| Feb 5, 2009 | PLIN | ↑ Buy | 2,648 | $7.80 | $21K | Indirect | Feb 6, 2009 (1d) |
| Jan 27, 2009 | PLIN | ↑ Buy | 7,707 | $8.04 | $62K | Indirect | Jan 27, 2009 (0d) |
| Jan 22, 2009 | PLIN | ↑ Buy | 3,515 | $8.07 | $28K | Indirect | Jan 23, 2009 (1d) |
| Jan 20, 2009 | PLIN | ↑ Buy | 9,882 | $8.14 | $80K | Indirect | Jan 20, 2009 (0d) |
| Jan 13, 2009 | PLIN | ↑ Buy | 6,911 | $7.03 | $49K | Indirect | Jan 15, 2009 (2d) |
| Sep 14, 2007 | MEMY | ↓ Sell | 27,600 | $2.10 | $58K | Indirect | Sep 18, 2007 (4d) |
| Sep 13, 2007 | MEMY | ↓ Sell | 72,180 | $2.13 | $154K | Indirect | Sep 14, 2007 (1d) |
| Dec 18, 2006 | MEMY | ↑ Buy | 2,315,151 | $1.11 | $2.6M | See Remarks | Jan 5, 2007 (18d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
About Vort John Vander's insider trades
Vort John Vander is a director at Aratana Therapeutics (PETX). Since Dec 18, 2006, Vort has reported 13 open-market purchases worth $15.4M and 4 sales worth $14.3M on SEC Form 4. There have been no open-market trades in the last 12 months.
Their filings also include other transactions (7 filings), grants and awards (6 filings), conversions (5 filings), shares returned to the company (2 filings). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every PETX insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.